ENDRA Life Sciences amends merger deal with ASP Isotopes affiliate, drops classified board requirement

• Merger terms were amended for ENDRA Life Sciences’ planned combination with ASP Isotopes unit Noble Africa, which would become ENDRA’s subsidiary.
• Cash closing condition was reset to $3,800,002.59, net of certain agreed expenses tied to investor relations activities.
• Post-close governance was revised to drop a classified board structure, with related charter changes removing supermajority voting provisions.
• Warrants held by an ASP affiliate were modified to remove a 4.99% beneficial ownership cap on exercise.
• Renergen’s borrowing capacity under an ASPI term loan facility was lifted to $120 million, with a further increase to $200 million contemplated by closing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-105899), on October 01, 2026, and is solely responsible for the information contained therein.